Adaptix Ortho350 Gains CE Mark for Orthopaedic Imaging

Avingtrans’s medical imaging subsidiary Adaptix has received CE certification for the Ortho350, a low-dose 3D orthopaedic imaging system designed for point-of-care use. Announced on 12 May 2026, the approval opens UK and European human healthcare markets to a platform Adaptix already supplies to veterinary and industrial non-destructive testing customers. The certification marks a commercial inflection point for the AIM-listed engineering group’s medical imaging business.

The Ortho350 is a compact, mobile system designed for imaging upper and lower extremities, including hands, elbows, shoulders, knees and feet. Adaptix, based at the Oxford University Science Park, develops low-dose 3D digital tomosynthesis imaging platforms intended for point-of-care environments rather than centralised radiology suites. Avingtrans says the system delivers high-resolution 3D X-ray imaging at a fraction of the radiation dose of traditional CT, at lower cost, with clearer images than conventional 2D X-ray, faster patient workflows and improved diagnostic confidence.

The CE mark confirms that the Ortho350 meets EU and UK safety, health and environmental protection requirements, formally opening the human imaging market across both regions. Adaptix already commercialises the same underlying 3D imaging technology through its VetSA3D veterinary product line and NDT3D industrial non-destructive testing range, providing an established manufacturing and service base for the human imaging rollout. Stuart Gall, chief executive of the medical and industrial imaging division, described the approval as a defining moment in the company’s stated mission to transform radiology.

With CE certification now secured, the commercial test for Adaptix is converting an established veterinary and industrial customer base into NHS and European clinical adoption, where point-of-care extremity imaging is a recognised gap. Avingtrans’s share reaction on the day was modest at around 2.4%, suggesting the market is waiting to see contract wins before fully repricing the medical imaging division.